Lupus anticoagulant: Performance of the tests as recommended by the latest ISTH guidelines

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 9, 2011, Pages 1776-1783

  Swadzba, J ^a   Iwaniec, T ^a   Pulka, M ^a   De Laat, B ^b,c,d   De Groot, P G ^b   Musial, J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

2GPI dependent LA; Double LA positivity; Guidelines; Lupus anticoagulant

Indexed keywords

ANTIVITAMIN K; BETA2 GLYCOPROTEIN 1; LUPUS ANTICOAGULANT; REAGENT;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE DISEASE; DILUTED RUSSEL VIPER VENOM TIME; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THROMBOSIS; VEIN THROMBOSIS;

ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTHROMBIN TIME; RETROSPECTIVE STUDIES; THROMBOSIS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 80052392227     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04420.x     Document Type: Article

References (42)

1. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Haemost Thromb 1972; 1: 75-95.
2. Conley CL, Hartmann RC. A haemorrhage disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Lab Clin Invest 1952; 31: 621-2.
3. Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-30.
4. Harris EN, Gharavi AE, Boey ML, Patel BM, Loizou S, Hughes GR. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in lupus erythematosus. Lancet 1983; 2: 1211-4.
5. Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to plasma protein cofactor. Lancet 1990; 335: 1544-7.
6. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes the lipid binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
7. Bevers EM, Galli M, Barbui T, Comfurius P, Zwall RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
8. Galli M, Luciani D, Bertollini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systemic review of the literature. Blood 2003; 101: 1827-32.
9. Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26: 324-6.
10. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette J-C, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-11.
11. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
12. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost 1991; 65: 320-2.
13. Brandy JT, Triplett DA, Alving B, Scharer I. Criteria for diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
14. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7: 1737-40.
15. Tripodi A. Testing for lupus anticoagulants: all that a clinician should know. Lupus 2009; 4: 291-8.
16. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 1999; 81: 929-34.
17. Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, de Candia E, Montaruli B, Testa S, Barcellona D, Tripodi A. Survey on lupus anticoagulant diagnosis by central evaluation of positive plasma samples. Thromb Haemost 2007; 5: 925-30.
18. Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 1999; 81: 256-8.
19. Urbanus RT, Derksen RH, de Groot PG. Current insight into diagnostics and pathophysiology of antiphospholipid syndrome. Blood Rev 2008; 2: 93-105.
20. Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by national survey using lyophilized affinity purified immunoglobulin with LA activity. Clin Chem 2003; 49: 1608-14.
21. Lambert M, Ferrard-Sasson G, Dubucquoi S, Hachulla E, Prin L, Hatron PY, Goudemand J, Boffa MC, Caron C. Diluted Russell viper-venom time improves identification of antiphospholipid syndrome in a lupus anticoagulant-positive patient population. Thromb Haemost 2009; 101: 577-81.
22. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin cloting time and dilute Russell viper venom timedistinguish between prothrombin dependent and beta -2 glycoprotein-I - dependent antiphospholipid antibodies. Blood 1995; 86: 617-23.
23. Dragoni F, Minotti C, Palumbo G, Faillace F, Redi R, Bongarzoni V, Avvisati G. As compared to kaolin clotting time, silica clotting time is a specific and sensitive automated method for detecting lupus anticoagulant. Thromb Res 2001; 101: 45-51.
24. Ames PR, Iannaccone L, de Lasio R, Brancacio V. Improved confirmation of weak lupus anticoagulants by employing sensitive and insensitive reagents to the lupus anticoagulant. Blood Coagul Fibrynolisis 2001; 12: 563-7.
25. Triplett DA, Stocker KF, Unger GA, Barna LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70: 925-31.
26. Swadźba J, de Clerck LS, Stevens WJ, Bridts CH, van Cotthem KA, Musial J, Jankowski M, Szczeklik A. Anticardiolipin antibodies, anti-β2-glycoprotein I, antiprothrombin antibodies and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997; 24: 1710-5.
27. Simmelink MJA, Derksen RHWM, Arnout J, de Groot PG. A simple method to discriminate between beta2-glycoprotein I and prothrombin dependent lupus anticoagulants. J Thromb Haemost 2003; 1: 740-7.
28. Pengo J, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to indentify anti beta2-glycoprotein I lupus anticoagulants. Thromb Haemost 2004; 2: 702-7.
29. De Laat B, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. Beta2 glycoprotein-I - dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598.
30. De Laat B, Derksen RHWM, Reber G, Musial J, Swadzba J, Bozic B, Cucnic S, Regnault V, Forastiero R, Woodhams BJ, de Groot PG. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost 2011; 9: 149-53.
31. Pengo J, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, Barcellona D, Tripodi A. A comparison of lupus anticoagulant positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol 2007; 27: 309-10.
32. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
33. Horbach DA, van Oort E, Donders CJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is a strongest risk factor for both venous and arterial thrombosis in patient with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.
34. Musial J, Swadzba J, Motyl A, Iwaniec T. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. J Rheumatol 2003; 30: 723-30.
35. Swadzba J, Iwaniec T, Szczeklik A, Musial J. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases. J Thromb Haemost 2007; 5: 1883-9.
36. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010; 19: 419-23.
37. Opatrny L, David M, Kahn SR. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune diseases: a metaanalysis. J Rheumatol 2006; 33: 2214-21.
38. Galli M, Reber G, de Moerloose P, de Groot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 399-401.
39. Swadzba J, Musial J. More on: the debate on antiphospholipid syndrome classification criteria. J Thromb Haemost 2009; 7: 501-2.
40. Pengo V, Banzato A, Bison E, Denas G, Padayattil Jose S, Ruffatti A. Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus 2010; 19: 428-31.
41. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lacos G, Tincani A, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Baleva M, Mosca M, Bombardieri S, Housiau F, Gris JC, Quere I, Hachulla E, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-27.
42. De Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, Ruffatti A, Rozman B, Kveder T, de Moerloose P, Boehlen F, Rand J, Ulcova-Gallova Z, Mertens K, de Groot PG. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-73.